Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 2/20 | 0.40 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.40 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.40 |
| ▸ | CHRM5 | P08912 | 5/20 | 0.37 |
| ▸ | CHRM3 | P20309 | 5/20 | 0.37 |
| ▸ | CHRM2 | P08172 | 5/20 | 0.37 |
| ▸ | CHRM1 | P11229 | 4/20 | 0.37 |
| ▸ | CHRM4 | P08173 | 4/20 | 0.37 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.36 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5648379 | 1.00 | CHRNB2 (0.40) | CHRNB2CHRNA7CHRNA4CHRM5CHRM3 | |
| SCHEMBL7666599 | 0.69 | CHRNB2 (0.43) | CHRNB2CHRNA7CHRNA4CHRM5CHRM3 | |
| SCHEMBL16405081 | 0.69 | CHRNB2 (0.43) | CHRNB2CHRNA7CHRNA4CHRM5CHRM3 | |
| SCHEMBL634724 | 0.69 | CHRNB2 (0.43) | CHRNB2CHRNA7CHRNA4CHRM5CHRM3 | |
| Hydrochloric Acid SCHEMBL27828833 | 0.68 | CHRNB2 (0.42) | CHRNB2CHRNA7CHRNA4CHRM5CHRM3 | |
| Hydrochloric Acid SCHEMBL15169508 | 0.68 | CHRNB2 (0.42) | CHRNB2CHRNA7CHRNA4CHRM5CHRM3 | |
| Hydrochloric Acid SCHEMBL28603590 | 0.68 | CHRNB2 (0.42) | CHRNB2CHRNA7CHRNA4CHRM5CHRM3 | |
| SCHEMBL17791781 | 0.68 | CHRNB2 (0.44) | CHRNB2CHRNA7CHRNA4CHRM5CHRM3 | |
| SCHEMBL1813465 | 0.67 | SCN10A (0.38) | CHRNB2CHRNA7CHRNA4CHRM5CHRM3 | |
| SCHEMBL955469 | 0.67 | CHRM2 (0.41) | CHRNB2CHRNA7CHRNA4CHRM5CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103819459-B | Anti-Viral Compounds | 艾伯维巴哈马有限公司 | 2017-05-17 | — | — | CN | disclosed |
| CN-103172620-B | Anti-viral compounds | Abbott Labaoratories (BS) | 2014-10-29 | — | — | CN | disclosed |
| CN-103819459-A | Anti-Viral Compounds | Abbott Labaoratories | 2014-05-28 | — | — | CN | disclosed |
| CN-103819537-A | Anti-viral compounds | Abbott Labaoratories | 2014-05-28 | — | — | CN | disclosed |
| CN-102333772-B | Antiviral compounds | ABBOTT LAB | 2013-12-11 | — | — | CN | disclosed |
| CN-103172620-A | Anti-viral compounds | Abbott Labaoratories | 2013-06-26 | — | — | CN | disclosed |
| CN-102333772-A | Antiviral compounds | ABBOTT LAB | 2012-01-25 | — | — | CN | disclosed |
| US-7166586-B2 | Sulfonamide lactam inhibitors of FXa and method | BRISTOL MYERS SQUIBB CO. (US) | 2007-01-23 | — | — | US | disclosed |
| US-7166586-B2 | Sulfonamide lactam inhibitors of FXa and method | BRISTOL MYERS SQUIBB CO. (US) | 2007-01-23 | — | — | US | disclosed |
| US-7166586-B2 | Sulfonamide lactam inhibitors of FXa and method | BRISTOL MYERS SQUIBB CO. (US) | 2007-01-23 | — | — | US | disclosed |
| US-20040186134-A1 | Sulfonamide lactam inhibitors of FXa and method | O'CONNOR STEPHEN P (US) | 2004-09-23 | — | — | US | disclosed |
| EP-1358178-A2 | SULFONAMIDE LACTAM INHIBITORS OF FACTOR XA | Bristol-Myers Squibb Company (US) | 2003-11-05 | — | — | EP | disclosed |
| US-6555542-B1 | Factor Xa (FXa); useful as anticoagulants in the treatment of cardiovascular diseases associated with thrombosis | BRISTOL-MYERS SQUIBB COMPANY | 2003-04-29 | — | — | US | disclosed |
| WO-2002060894-A2 | SULFONAMIDE LACTAM INHIBITORS OF FACTOR XA | BRISTOL-MYERS SQUIBB COMPANY (US) | 2002-08-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040186134-A1 | Sulfonamide lactam inhibitors of FXa and method | STS, SULT1E1, F8 | CHRNB2 4869/4885CHRNA7 4629/4885CHRNA4 4607/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.